Table 2.
EECP (N=28) | SHAM (N=14) | P | |
---|---|---|---|
Prior CABG | 19 (76%) | 11 (79%) | .481 |
Prior PTCA | 23 (92%) | 12 (88%) | .776 |
Prior Myocardial Infarction | 17 (61%) | 6 (43%) | .284 |
Multivessil CAD | 25 (89%) | 13 (93%) | .718 |
Diabetes | 21 (84%) | 11 (79%) | .804 |
Hypertension | 23 (92%) | 12 (88%) | .776 |
Hyperlipidemia | 26 (93%) | 14 (100%) | .317 |
Lipid Lowering | 28 (100%) | 14 (100%) | .999 |
Beta-Blocker | 24 (86%) | 11 (79%) | .569 |
Calcium Channel Blocker | 11 (39%) | 6 (43%) | .829 |
Long Lasting NItrates | 25 (89%) | 12 (88%) | .744 |
ACE Inhibition (or)ARB | 26 (93%) | 12 (88%) | .469 |
Insulin | 9 (32%) | 5 (36%) | .822 |
There were no significant differences (p>0.05) in baseline characteristics, drug regimens, and cardiac intervention history between SHAM and EECP group at baseline. Values are presented as the number of patients per group and the percentage within each group.